Parkinson Disease
Neurologix signs license agreement for component of Parkinson gene therapy product
Published in Gene Therapy Weekly, September 7th, 2006
Under the terms of the agreement, Neurologix has been granted a license for the use of the glutamic acid decarboxylase (GAD) 65 gene, a component of the core technology "NLX-P101" gene therapy used in its recently completed, landmark Phase I clinical trial.
The company will pay Diamyd a license issue fee of $500,000 and will pay annual maintenance fees beginning in January 2008. Upon commercialization of the Parkinson's product, the company will also make certain milestone and royalty payments.
"The company may now go forward with...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2006-09-07)
More Articles from Gene Therapy Weekly
- Antisense Therapy
Dystrophin expression induced by antisense oligonucleotides - Infectious Diseases
Distinct roles for resistance to oral candidiasis defined by gene-targeting - Mucopolysaccharidoses
Mucopolysaccharidoses therapy achieved by gene expression-targeted therapy - RNA Interference
RNA interference aids in inhibiting cell proliferation and gene expression - RNA Research
Effective RNAi probes screened and identified in mammalian cells - Acute Myeloid Leukemia
Dacogen (decitabine) for Injection receives U.S. orphan drug designation for patients with AML - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
